NCT00337454 - Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG

Dasatinib

Tablets, Oral, 50mg BID, once daily, 24 weeks.

DRUG

Dasatinib

Tablets, Oral, 70mg BID, once daily, 24 weeks.

DRUG

Dasatinib

Tablets, Oral, 90mg BID, once daily, 24 weeks.

DRUG

Dasatinib

Tablets, Oral, 70mg BID, once daily, 24 weeks.

DRUG

Dasatinib

Tablets, Oral, 70mg BID, once daily, 12 weeks.

DRUG

Dasatinib

Tablets, Oral, 70mg BID, once daily, 12 weeks.

Trial Locations (21)

464-8681

Local Institution, Nagoya

466-8550

Local Institution, Nagoya

467-8602

Local Institution, Nagoya

371-0821

Local Institution, Maebashi

663-8501

Local Institution, Nishinomiya-Shi

890-0064

Local Institution, Kagoshima

259-1193

Local Institution, Isehara-Shi

Unknown

Local Institution, Kanagawa

Local Institution, Kyoto

Local Institution, Sendai

Local Institution, Nagasaki

Local Institution, Tokyo

700-0082

Local Institution, Okayama

570-8540

Local Institution, Moriguchi

350-0495

Local Institution, Iruma-Gun

431-3192

Local Institution, Hamamatsu

329-0498

Local Institution, Tochigi

113-8677

Local Institution, Bunkyo-Ku

104-0045

Local Institution, Chuo-Ku

160-8582

Local Institution, Shinjuku-Ku

162-8666

Local Institution, Shinjuku-Ku